Amazing Meds: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://amazing-meds.com in August 2025 and has observed that your website offers various compounded drug products, including retatrutide and semaglutide. As described below, your retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 355(a), 352(f)(1), 331(a) and 331(d)]. In addition, your claim concerning compounded semaglutide products is false or misleading under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)] resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].

1. 1

   “Your compounded retatrutide drug products fail to meet the conditions of sections 503A and 503B. Drug products compounded using retatrutide are not eligible for the exemptions provided by section 503A, because retatrutide is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list.”

2. 2

   “There are no FDA-approved applications on file for your compounded retatrutide drug products. Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 355(a) and 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.”

3. 3

   “The following claim regarding your compounded semaglutide products appears on your website:”

4. 4

   “Compounded semaglutide (same as Ozempic/Wegovy)”

5. 5

   “Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

amazing-meds.com resolved and returned a complete, functioning storefront to a direct fetch on 2026-08-09 — a served homepage with working navigation, not a placeholder, a parking page or an error. That is a check of whether the site is up; it is not a check of anything the letter alleges.

Most letters in this index are about the wording on a page: change the sentence and the objection is answered. This one is only half that. The semaglutide half is a wording finding, and a small one — a six-word parenthetical. The retatrutide half is not about wording, and no rewrite reaches it, because FDA's point is that no approved application exists for those products and that the compounding exemptions in sections 503A and 503B do not cover them. For someone comparing prices, that is the distinction worth carrying: a claim can be edited overnight, an approval status cannot. It is also worth being precise about what the letter does not say. It makes no finding that anything was contaminated, badly made or unfit — approval is a question about paperwork and review, not a verdict on the vial — and the two halves should not be collapsed into one.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Amazing Meds failed to respond.